Kerendia 10mg (Finerenone)

Kerendia (generic name: Finerenone) is an extremely modern and novel medication, which has been deemed safe to be used by patients suffering from chronic kidney diseases (CKD) associated with type 2 diabetes (T2D). It is a major step forward in managing the intricate relationship between kidney function, blood sugar levels, and heart health.

In this blog article this blog post, we’ll provide a thorough examination of Kerendia 10 mg, its uses and how it functions, advantages, adverse effects, as well as important warnings you need to be informed of.

What is Kerendia (Finerenone)?

Kerendia, an oral medicine that contains Finerenone (a non-steroidal antagonist of the mineralocorticoid receptor (MRA). It’s employed for its ability to reduce the development of kidney diseases in those suffering from type 2 diabetes and also to lower the chance of heart-related issues, including cardiovascular failure and heart failure.

Kerendia was formally approved by the U.S. FDA in July 2021, and since then has been accepted as a viable therapy option in nephrology and cardiology.

How Does Kerendia Work?

Finerenone acts through inhibiting mineralocorticoid receptors (MRs) in the kidneys, the heart, as well as blood vessels. The receptors are stimulated by hormones such as aldosterone and play a part in the regulation of blood pressure as well as inflammation and fibrosis (scarring of tissues).

If you have diabetes or CKD, overactivation of MR receptors is a cause of:

• Inflammation in the kidneys
• Fibrosis (tissue scarring)
• Progressive loss of kidney function
• Increased risk of cardiovascular events

Through specifically blocking the receptors, Finerenone reduces inflammation and fibrosis within both the kidneys as well as the heart and the heart, reducing disease progression and decreasing the chance of developing complications.

Indications: What is Kerendia 10 mg Used For?

Kerendia 10 mg can be utilized as:

• Lowering the chance of chronic decrease in kidney function and end-stage kidney disease (ESKD), heart disease, death from cardiovascular causes, nonfatal heart attacks, and hospitalization due to heart failure in adult patients with:
  • Chronic kidney disease (CKD)
  • Type 2 diabetes (T2D)

It’s typically recommended in conjunction with standard treatments for CKD and diabetes, like ARBs or ACE inhibitors, but it is not meant to be a substitute for blood pressure or blood sugar medication.

Dosage and Administration

Kerendia is offered as dosages of 10 and 20 mg tablets for oral use. The dosage that is recommended for the initial dose will depend on kidney functioning, which is measured by the eGFR (estimated glomerular filter rate).

• eGFR ≥60 mL/min/1.73 m²: Begin with 20 mg once a day
• eGFR 25–59 mL/min/1.73 m²: Begin by taking 10 mg once a day, gradually increasing to 20 mg when tolerated.
• eGFR <25 mL/min/1.73 m²: It is not advised to use it.

Administration tips:

• Do it once a day, with or without food
• Take your medication at the same time throughout the day.
• Don’t take a second dose if you miss a dose; take the next dose prescribed

Benefits of Kerendia

1. Slows Kidney Disease Progression

In clinical studies, people who were taking Finerenone were found to have noticeably slower declines in kidney function in comparison to those who received a placebo, regardless of whether they were already receiving regular medical care.

2. Protects the Heart

Kerendia reduces the risk for cardiovascular failure, non-fatal myocardial infarction (heart attack), and the death of a cardiovascular patient–a significant concern for people suffering from CKD as well as T2D.

3. Anti-inflammatory and Anti-fibrotic Effects

Contrary to earlier steroids, MRAs (like Spironolactone), Finerenone can be more specific and has fewer hormone-related side effects.

4. Well-Tolerated

It’s generally well-tolerated and has it having a very low possibility of high potassium (high sodium) compared to other MRAs.

Clinical Trials Supporting Kerendia

FIDELIO-DKD and FIGARO-DKD Trials

The two clinical trials of these large scales included more than 13,000 people who suffer from CKD or type 2 diabetes:

• FIDELIO-DKD focused on kidney outcomes
• FIGARO-DKD focused on cardiovascular outcomes

Key findings:

• Finerenone has reduced the likelihood of progression of kidney disease by as much as 18%
• Also, it reduced the chance of cardiovascular-related events by 13.1 to 14.4%.

These findings proved Finerenone as an effective fundamental treatment for the treatment of diabetes-related kidney disease.

Side Effects of Kerendia

Similar to all drugs, Kerendia may cause side effects. Most commonly, they include:

Common side effects:

• Hyperkalemia (high blood potassium levels)
• Low blood pressure (hypotension)
• Dizziness or lightheadedness
• Dehydration

Less common but serious side effects:

• Kidney function deterioration (rare but possible)
• Electrolyte imbalance

Monitoring:

• The levels of potassium in the blood and kidney functionality (eGFR) must be checked before starting the treatment and frequently throughout the course of treatment.
• Patients with elevated baseline potassium levels could need dosage adjustment or even removal.

Precautions and Warnings

Before you begin Kerendia, inform your doctor about the following:

• Are suffering from kidney problems that aren’t related to diabetes
• Have high potassium levels
• Are taking potassium-sparing diuretics, NSAIDs, or ACE inhibitors/ARBs
• Have low blood pressure
• Are pregnant or breastfeeding (Kerendia is not recommended during pregnancy)

Kerendia is a medication to be avoided for patients who are elderly or who are taking medications that can increase potassium levels.

Drug Interactions

Kerendia can interact with:

• Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin) – can increase levels of Finerenone dangerously
• Potassium supplements or potassium-sparing diuretics – could increase the risk of hyperkalemia
• NSAIDs – could lower kidney function when it is combined with

Your physician may alter the dosage or eliminate certain drugs to guarantee the safety of your children.

Kerendia vs. Other MRAs

Compared to the traditional MRAs that include Spironolactone or Eplerenone, Kerendia is a different MRA:

• Has less hormonal side effects (e.g., no gynecomastia, impotence)
• Being more targeted means that there is less risk of off-target effects
• Is there more heart-kidney protection when patients suffer from diabetes and CKD

Storage Instructions

• Maintain the room temperatures (20–25°C or 68–77°F)
• In the original package, away from moisture and temperatures
• Maintain Make sure that the items are out of children’s reach.

Final Thoughts

Kerendia 10 mg (Finerenone) is a revolutionary therapy that can fill one of the major gaps in the therapy of chronic kidney disease, which is common in type 2 diabetes. Through addressing inflammation and fibrosis on the mineralocorticoid receptor, the drug has a double benefit- safeguarding both kidneys as well as the heart.